{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:19:02Z","timestamp":1792441142470,"version":"4.5.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.20166","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T19:48:40Z","timestamp":1602186520000},"page":"e2020166","source":"Crossref","is-referenced-by-count":65,"title":["Oral \u03b2-Lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia From a Urine Source"],"prefix":"10.1001","volume":"3","author":[{"given":"Jesse D.","family":"Sutton","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah"},{"name":"IDEAS Center of Innovation, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa W.","family":"Stevens","sequence":"additional","affiliation":[{"name":"IDEAS Center of Innovation, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah"},{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Chung N.","family":"Chang","sequence":"additional","affiliation":[{"name":"IDEAS Center of Innovation, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah"},{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Khader","sequence":"additional","affiliation":[{"name":"IDEAS Center of Innovation, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah"},{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan T.","family":"Timbrook","sequence":"additional","affiliation":[{"name":"IDEAS Center of Innovation, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah"},{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City"},{"name":"now at BioFire Diagnostics, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S.","family":"Spivak","sequence":"additional","affiliation":[{"name":"IDEAS Center of Innovation, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah"},{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"issue":"5","key":"zoi200697r1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1001\/jama.2012.8262","article-title":"Does this adult patient with suspected bacteremia require blood cultures?","volume":"308","author":"Coburn","year":"2012","journal-title":"JAMA"},{"issue":"5","key":"zoi200697r2","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"5","key":"zoi200697r3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/650482","article-title":"Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America.","volume":"50","author":"Hooton","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi200697r4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/archinte.159.1.53","article-title":"Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial.","volume":"159","author":"Mombelli","year":"1999","journal-title":"Arch Intern Med"},{"issue":"10","key":"zoi200697r5","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/jac\/dkt177","article-title":"Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection\u20147 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials.","volume":"68","author":"Eliakim-Raz","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"zoi200697r6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamainternmed.2018.6226","article-title":"Association of 30-day mortality with oral step-down vs continued intravenous therapy in patients hospitalized with Enterobacteriaceae bacteremia.","volume":"179","author":"Tamma","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"5","key":"zoi200697r7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijantimicag.2016.07.013","article-title":"Effectiveness of oral antibiotics for definitive therapy of gram-negative bloodstream infections.","volume":"48","author":"Kutob","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"zoi200697r8","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14656566.2019.1594774","article-title":"Clinical considerations for oral beta-lactams as step-down therapy for Enterobacteriaceae bloodstream infections.","volume":"20","author":"Mogle","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"zoi200697r9","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijantimicag.2017.12.010","article-title":"Management of bloodstream infections by infection specialists: an international ESCMID cross-sectional survey.","volume":"51","author":"Diallo","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"zoi200697r10","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz386","article-title":"Practice patterns of infectious diseases physicians in transitioning from intravenous to oral therapy in patients with bacteremia.","author":"Hospenthal","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"zoi200697r11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.cmi.2019.05.012","article-title":"Transition from intravenous to oral antimicrobial therapy in patients with uncomplicated and complicated bloodstream infections.","volume":"26","author":"Al-Hasan","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"zoi200697r13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02236-16","article-title":"Antimicrobial resistance of Escherichia coli urinary isolates in the Veterans Affairs health care system.","volume":"61","author":"Morrill","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"zoi200697r14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/cid\/cix733","article-title":"Rates of and risk factors for adverse drug events in outpatient parenteral antimicrobial therapy.","volume":"66","author":"Keller","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"12","key":"zoi200697r15","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10096-019-03679-9","article-title":"A pharmacokinetic\u2013pharmacodynamic assessment of oral antibiotics for pyelonephritis.","volume":"38","author":"Cattrall","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"zoi200697r16","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz364","article-title":"Oral fluoroquinolone or trimethoprim-sulfamethoxazole vs. \u00df-lactams as step-down therapy for Enterobacteriaceae bacteremia: systematic review and meta-analysis.","volume":"6","author":"Punjabi","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"zoi200697r17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13063-015-0688-z","article-title":"Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): study protocol for a pilot randomized controlled trial.","volume":"16","author":"Daneman","year":"2015","journal-title":"Trials"},{"issue":"7","key":"zoi200697r18","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores.","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"zoi200697r19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/2013.jamainternmed.829","article-title":"Urinary tract infection in male veterans: treatment patterns and outcomes.","volume":"173","author":"Drekonja","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"1","key":"zoi200697r20","first-page":"250","article-title":"Addressing extreme propensity scores via the overlap weights.","volume":"188","author":"Li","year":"2019","journal-title":"Am J Epidemiol"},{"issue":"23","key":"zoi200697r21","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial.","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"zoi200697r22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ijantimicag.2017.12.007","article-title":"Retrospective analysis comparing oral stepdown therapy for Enterobacteriaceae bloodstream infections: fluoroquinolones versus \u00df-lactams.","volume":"51","author":"Mercuro","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"zoi200697r23","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.cmi.2018.01.013","article-title":"Treatment duration for Escherichia coli bloodstream infection and outcomes: retrospective single-centre study.","volume":"24","author":"Giannella","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"zoi200697r24","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s10096-019-03467-5","article-title":"Short- versus long-course therapy in gram-negative bacilli bloodstream infections.","volume":"38","author":"Sousa","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"zoi200697r27","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","article-title":"Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial.","volume":"69","author":"Yahav","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"21","key":"zoi200697r28","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-reactive protein\u2013guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial.","volume":"323","author":"von Dach","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"zoi200697r29","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/cid\/ciy1057","article-title":"Shortening antibiotic treatment durations for bacteremia.","volume":"69","author":"Daneman","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"10","key":"zoi200697r30","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial.","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"zoi200697r31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13063-018-2474-1","article-title":"7 Versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial.","volume":"19","author":"Daneman","year":"2018","journal-title":"Trials"},{"issue":"3","key":"zoi200697r32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/0003-4819-106-3-341","article-title":"Acute renal infection in women: treatment with trimethoprim-sulfamethoxazole or ampicillin for two or six weeks. a randomized trial.","volume":"106","author":"Stamm","year":"1987","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi200697r33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF01973737","article-title":"Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis.","volume":"9","author":"Sandberg","year":"1990","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"zoi200697r34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1988.tb15899.x","article-title":"One or three weeks\u2019 treatment of acute pyelonephritis? a double-blind comparison, using a fixed combination of pivampicillin plus pivmecillinam.","volume":"223","author":"Jernelius","year":"1988","journal-title":"Acta Med Scand"},{"issue":"2","key":"zoi200697r35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/infdis\/163.2.325","article-title":"Therapy for women hospitalized with acute pyelonephritis: a randomized trial of ampicillin versus trimethoprim-sulfamethoxazole for 14 days.","volume":"163","author":"Johnson","year":"1991","journal-title":"J Infect Dis"},{"issue":"5","key":"zoi200697r36","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/00365549509047047","article-title":"Ampicillin plus mecillinam vs. cefotaxime\/cefadroxil treatment of patients with severe pneumonia or pyelonephritis: a double-blind multicentre study evaluated by intention-to-treat analysis.","volume":"27","author":"Cronberg","year":"1995","journal-title":"Scand J Infect Dis"},{"issue":"4, pt 1","key":"zoi200697r37","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0029-7844(95)80016-6","article-title":"Outpatient treatment of pyelonephritis in pregnancy: a randomized controlled trial.","volume":"86","author":"Millar","year":"1995","journal-title":"Obstet Gynecol"},{"issue":"2","key":"zoi200697r38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/00365549709035880","article-title":"Aminoglycosides do not improve the efficacy of cephalosporins for treatment of acute pyelonephritis in women.","volume":"29","author":"Sandberg","year":"1997","journal-title":"Scand J Infect Dis"},{"issue":"14","key":"zoi200697r39","first-page":"521","article-title":"Cefixime versus amoxicillin plus netilmicin in the treatment of community-acquired non-complicated acute pyelonephritis.","volume":"111","author":"Moreno-Mart\u00ednez","year":"1998","journal-title":"Med Clin (Barc)"},{"issue":"1","key":"zoi200697r40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/emj.19.1.19","article-title":"Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women: a randomised controlled trial.","volume":"19","author":"Sanchez","year":"2002","journal-title":"Emerg Med J"},{"issue":"12","key":"zoi200697r41","doi-asserted-by":"crossref","first-page":"e843","DOI":"10.1016\/j.ijid.2012.07.009","article-title":"A prospective, randomized, double dummy, placebo-controlled trial of oral cefditoren pivoxil 400 mg once daily as switch therapy after intravenous ceftriaxone in the treatment of acute pyelonephritis.","volume":"16","author":"Monmaturapoj","year":"2012","journal-title":"Int J Infect Dis"},{"issue":"22","key":"zoi200697r42","first-page":"2192","article-title":"Urinary tract infections in older men.","volume":"374","author":"Schaeffer","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi200697r43","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cmi.2016.10.023","article-title":"Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition.","volume":"23","author":"Harris","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"zoi200697r44","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/cid\/ciy043","article-title":"Duration of antimicrobial therapy for Enterobacteriaceae bacteremia: using convenient end points for convenient conclusions.","volume":"66","author":"Al-Hasan","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"12","key":"zoi200697r45","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/cid\/ciy046","article-title":"Reply to Al-Hasan et al.","volume":"66","author":"Chotiprasitakul","year":"2018","journal-title":"Clin Infect Dis"},{"key":"zoi200697r46","author":"Clinical and Laboratory Standards Institute"},{"issue":"12","key":"zoi200697r47","article-title":"Impact of an antimicrobial stewardship bundle for uncomplicated gram-negative bacteremia.","volume":"6","author":"Erickson","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"zoi200697r48","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1478-7954-4-2","article-title":"Accuracy and completeness of mortality data in the Department of Veterans Affairs.","volume":"4","author":"Sohn","year":"2006","journal-title":"Popul Health Metr"},{"issue":"6","key":"zoi200697r49","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/cid\/cix474","article-title":"Management of bacteriuria in Veterans Affairs hospitals.","volume":"65","author":"Spivak","year":"2017","journal-title":"Clin Infect Dis"},{"key":"zoi200697r12","unstructured":"US Food and Drug Administration. FDA drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Published May 12, 2016. Accessed March 15, 2020. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm511530.htm"},{"key":"zoi200697r25","unstructured":"Mao? H, Li? L. PSW: propensity score weighting methods for dichotomous treatments. R package version 1.1-3. Published 2018. Accessed March 15, 2020. https:\/\/cran.r-project.org\/package=PSW"},{"key":"zoi200697r26","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. Guidance document: complicated urinary tract infections: developing drugs for treatment. Published June 2018. Accessed June 23, 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/complicated-urinary-tract-infections-developing-drugs-treatment"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2771521\/sutton_2020_oi_200697_1601603751.0893.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T19:49:30Z","timestamp":1602186570000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2771521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.20166","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,8]]}}}